ALS biomarker research
Not Applicable
Recruiting
- Conditions
- amyotrophic lateral sclerosis (ALS)ALS
- Registration Number
- JPRN-jRCTs051180229
- Lead Sponsor
- Inoue Haruhisa
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 49
Inclusion Criteria
Those who agree to attend the current clinical study among ALS patients joining an accompanying clinical trial Phase 1/2 Dose Escalation Study of Bostinib in Patients with Amyotrophic Lateral Sclerosis (ALS)
Exclusion Criteria
N/A
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Alteration of blood biomerkers including SOD1, TDP-43, Src, c-Abl, etc. <br>Alteration of CSF biomerkers including neurofilament L, phosphorylated neurofilament H, SOD1, TDP-43, etc.<br>Alteration of urine biomerkers including p75, etc.<br>Plasma concentration of bosutinib (through value)<br>CSF concentration of bosutinib (through value)<br>Evaluation of biomerkers using iPS cells
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular biomarkers are being investigated in the JPRN-jRCTs051180229 ALS trial for disease progression tracking?
How does the JPRN-jRCTs051180229 trial compare to other interventional studies in identifying ALS-specific biomarkers for patient stratification?
What are the potential adverse events associated with biomarker-based interventions in amyotrophic lateral sclerosis clinical trials?
Are there any novel drug targets or compounds being explored in the JPRN-jRCTs051180229 trial for ALS treatment development?
How effective are current ALS biomarkers in predicting treatment response compared to those under investigation in the JPRN-jRCTs051180229 study?